Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …

In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with
checkpoint inhibitors is still not very clear. We utilize single-cell RNA-and ATAC-sequencing …

1015 Background: Atezolizumab (anti-PD-L1) plus nab-paclitaxel was shown to improve
outcomes in mTBNC in a phase III clinical trial. Subjects were required to be> 12 months …

Currently there is a limited understanding for the optimal combination of immune checkpoint
inhibitor and chemotherapy for patients with metastatic triple-negative breast cancer …

Purpose Immunotherapy has recently been shown to improve outcomes for advanced PD-
L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA …

Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic
chemotherapy is a promising therapeutic modality for women with triple-negative breast …

Abstract Background: In mTNBC, anti-PD-1/L1 monotherapy is most effective when
administered early in the course of disease, with recent trials demonstrating overall …

Purpose Triple negative breast cancer (TNBC) is characterized by the presence of immune
cells in the tumor microenvironment, however, the response to single-agent immune …

Purpose Circulating tumor cells (CTCs) are prognostic biomarkers in metastatic breast
cancer, but their role in predicting treatment outcomes in metastatic triple-negative breast …

The evolutionary changes in immune profiles of triple negative breast cancer (TNBC) are not
well understood, although it is known that immune checkpoint inhibitors have diminished …